肝癌合并门脉癌栓的化疗栓塞治疗  

Chemoembolization of Hepatocellular Carcinoma with Portal Vein Thrombosis

作　　者：刘崎[1] 贾雨辰[1] 贺佳[1] 王振堂[1] 田建明[1] 叶华[1] 陆建平[1] 王飞[1] 杨继金[1] 孙飞[1] 陈栋[1] 林琳[1] 

机构地区：[1]第二军医大学附属长海医院

出　　处：《中华放射学杂志》1995年第4期239-242,共4页Chinese Journal of Radiology

摘　　要：１２８例肝癌合并门脉癌栓病人经２次以上插管治疗，Ａ组肝动脉内灌注化疗药物，Ｂ组药物灌注加碘油栓塞，Ｃ组化疗加碘油及明胶海绵粒栓塞。三组１年生存率分别为２５．００％，２８．５２％，４１．７６％，平均生存７．２个月、８．４个门及１０．３个月。Ｃ组疗效最好，１例病人存活达７年。说明，门脉癌栓不应是肝动脉化疗栓塞的禁忌证，对没有严重肝硬化及肝功能损害的门脉癌栓病人均应进行化疗栓塞治疗。One hundred twenty-eight patients of hepatocellular carcinoma with portal vein thrombosis underwent more than 2 times interventional treatnient.The patients were divided into 3 groups according to the method of therapy, group A, hepatic transarterial chemotherapy alone;group B,chemotherapy and lipiodol embolization ,group C,chemotherapy,lipiodol and gelfoam em-bolization,The one year survival rates of the three groups were 25.00%, 28.52% and 41.76%,re-spectively. The median durations of survival were 7.2.8.4 and 10.3 months respectively. The cura-tive effect of group C was the best and included one long-term:urvivor(>7years); The results showed that portal vein thrombosis should not be considered as contraindication to hepatic chemoem-bolization which could be used if hepatic cirrhosis is not severe and liver functions are not severelv im-paired.

关 键 词：肝肿瘤 门静脉 癌栓 药物疗法 栓塞疗法 

分 类 号：R735.705[医药卫生—肿瘤]